drugset / Trial / NCT00400855

Study on the Effects of an AMP Challenge on Asthmatic Patients Following Treatment With Fluticasone Propionate

NCT00400855

Phase 2 Completed 49 enrolled GlaxoSmithKline
RandomizedCrossoverDouble-blindTreatment

Summary

Inhaling AMP causes an inflammatory response in the lung. This study will investigate whether 5-days of treatment with fluticasone propionate protects the lung from responding to the AMP in this way.

Timeline

Start
2005-01
Primary completion
2005-08
Completion
2005-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluticasone propionate Other / unclassified Inhaled

Indications